EGFR and lung adenocarcinoma: In the LUX-Lung 3 study, PFS of patients with EGFR-mutated advanced lung adenocarcinoma was longer with afatinib than with doublet chemotherapy (11.1 vs. 6.9 months; HR = 0.58, 95% CI = 0.43–0.78, p = 0.001) [5].